The treatment field of Multiple Myeloma continues to move forward as novel agents and treatment combinations expand. Whether you are standard risk patient or belong to high-risk group, treatment paradigms are getting better. We are talking to Dr. Mateos on Myeloma research and treatment modalities discussed and presented at the recently concluded American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings.
Dr. Maria Victoria Mateos is PhD Director of the Myeloma Unit University Hospital of Salamanca-IBSAL Salamanca, Spain is an Associate Professor of Hematology and Consultant Physician of the Haematology Department at the University Hospital of Salamanca, Spain.
Sorry we couldn't complete your registration. Please try again.
You must accept the Terms and conditions to register